France's radiopharmaceuticals and theranostics market is estimated at USD 447 million in the current year and is projected to reach USD 1,032.8 million by 2035, representing a CAGR of approximately 9.8% during the forecast period, according to a report added to ResearchAndMarkets.com's offering. Growth is being supported by oncology demand, broader reimbursement pathways, advanced nuclear medicine infrastructure and investment in domestic radioisotope production. France's hospital-based nuclear medicine network, academic radiochemistry capabilities and manufacturing links to the French Atomic Energy Commission (CEA) ecosystem have helped establish its position in Europe's market. Curium is investing more than €32 million in a lutetium-177 PSMA-I&T production line at Saclay, following more than €50 million invested across 13 French production sites over five years. Orano Med is developing a €250 million Advanced Thorium Extraction Facility in Bessines-sur-Gartempe and an ATLab in Onnaing near Valenciennes; production at the ATLab is expected from 2026 and the facility is scheduled to become operational in 2027. Orano Med is also supported by a €125 million European Investment Bank credit line. Diagnostic radiopharmaceuticals currently lead the market, while therapeutic radiopharmaceuticals are expected to post the higher CAGR through 2035. Hospitals and university medical centers remain the largest end-user segment, although private diagnostic imaging centers are projected to grow more rapidly as PET and SPECT capacity expands. The report covers market sizing, forecasts, company profiles, production capacity, clinical trials, partnerships, funding, supply chains, reimbursement, distribution economics and competitive positioning across France.